Movement Alert｜Argenx SE Rises 3.55% in Pre-Market Trading, BNP Paribas Initiates Outperform Rating with $1,219 Target

Market Focus

06/24

On June 24, Argenx SE rose 3.55% in pre-market trading, trading at $868.83/share, with turnover of $20,300.

On the news front, BNP Paribas recently initiated coverage on Argenx with an Outperform rating and set a target price of $1,219, implying approximately 40% upside from the current stock price. According to FactSet data, the stock carries an average analyst rating of Buy with a mean target price of $1,064.53. BNP Paribas's target price stands notably above market consensus, providing a positive catalyst for sentiment and extending the stock's recent upward momentum.

Argenx SE is a commercial-stage global biopharmaceutical company focused on developing differentiated therapies for severe autoimmune diseases. Its lead product candidate, efgartigimod, targets conditions including myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, and chronic inflammatory demyelinating polyneuropathy. The company maintains strategic partnerships with AbbVie, Zai Lab, and LEO Pharma, among others.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/1148915961"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1148915961\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1148915961?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-24 16:07","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1148915961","market":"hk","top_or_hot":-1,"title":"Movement Alert｜Argenx SE Rises 3.55% in Pre-Market Trading, BNP Paribas Initiates Outperform Rating with $1,219 Target","media":"Market Focus","content":"<p><p>On June 24, Argenx SE rose 3.55% in pre-market trading, trading at $868.83/share, with turnover of $20,300.</p><p>On the news front, BNP Paribas recently initiated coverage on Argenx with an Outperform rating and set a target price of $1,219, implying approximately 40% upside from the current stock price. According to FactSet data, the stock carries an average analyst rating of Buy with a mean target price of $1,064.53. BNP Paribas's target price stands notably above market consensus, providing a positive catalyst for sentiment and extending the stock's recent upward momentum.</p><p>Argenx SE is a commercial-stage global biopharmaceutical company focused on developing differentiated therapies for severe autoimmune diseases. Its lead product candidate, efgartigimod, targets conditions including myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, and chronic inflammatory demyelinating polyneuropathy. The company maintains strategic partnerships with AbbVie, Zai Lab, and LEO Pharma, among others.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Argenx SE Rises 3.55% in Pre-Market Trading, BNP Paribas Initiates Outperform Rating with $1,219 Target</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Argenx SE Rises 3.55% in Pre-Market Trading, BNP Paribas Initiates Outperform Rating with $1,219 Target\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time smaller\">2026-06-24 16:07</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p><p>On June 24, Argenx SE rose 3.55% in pre-market trading, trading at $868.83/share, with turnover of $20,300.</p><p>On the news front, BNP Paribas recently initiated coverage on Argenx with an Outperform rating and set a target price of $1,219, implying approximately 40% upside from the current stock price. According to FactSet data, the stock carries an average analyst rating of Buy with a mean target price of $1,064.53. BNP Paribas's target price stands notably above market consensus, providing a positive catalyst for sentiment and extending the stock's recent upward momentum.</p><p>Argenx SE is a commercial-stage global biopharmaceutical company focused on developing differentiated therapies for severe autoimmune diseases. Its lead product candidate, efgartigimod, targets conditions including myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, and chronic inflammatory demyelinating polyneuropathy. The company maintains strategic partnerships with AbbVie, Zai Lab, and LEO Pharma, among others.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ARGX","symbol_name":"Argenx SE","start_time":0,"source_url":"","article_id":"1148915961","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1148915961","pubTimestamp":1782288462,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On June 24, Argenx SE rose 3.55% in pre-market trading, trading at $868.83/share, with turnover of $20,300.On the news front, BNP Paribas recently initiated coverage on Argenx with an Outperform...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ARGX":"Argenx SE"},"translate_title":"走势提示|Argenx SE盘前涨3.55%法巴启动跑赢大盘评级目标1219美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ARGX":1},"content_text":"On June 24, Argenx SE rose 3.55% in pre-market trading, trading at $868.83/share, with turnover of $20,300.On the news front, BNP Paribas recently initiated coverage on Argenx with an Outperform rating and set a target price of $1,219, implying approximately 40% upside from the current stock price. According to FactSet data, the stock carries an average analyst rating of Buy with a mean target price of $1,064.53. BNP Paribas's target price stands notably above market consensus, providing a positive catalyst for sentiment and extending the stock's recent upward momentum.Argenx SE is a commercial-stage global biopharmaceutical company focused on developing differentiated therapies for severe autoimmune diseases. Its lead product candidate, efgartigimod, targets conditions including myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, and chronic inflammatory demyelinating polyneuropathy. The company maintains strategic partnerships with AbbVie, Zai Lab, and LEO Pharma, among others.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}